Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.
Tara E SoumeraiMark T A DonoghueChaitanya BandlamudiPreethi SrinivasanMatthew T ChangDmitriy ZamarinKaren A CadooRachel N GrishamRoisin E O'CearbhaillWilliam P TewJason A KonnerMartee L HensleyVicky MakkerPaul SabbatiniDavid R SpriggsTiffany A Troso-SandovalAlexandra Snyder CharenClaire F FriedmanMila GorskySarah J SchweberSumit MiddhaRajmohan MuraliSarah ChiangKay J ParkRobert A SoslowMarc LadanyiBob T LiJennifer MuellerBritta WeigeltAhmet ZehirMichael F BergerNadeem R Abu-RustumCarol AghajanianDeborah F DeLairDavid B SolitBarry S TaylorDavid M HymanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)
Prospective clinical sequencing of advanced endometrial cancer can help refine prognosis and aid treatment decision making by simultaneously detecting microsatellite status, germline predisposition syndromes, and potentially actionable mutations. A small overall proportion of all patients tested received investigational, genomically matched therapy as part of clinical trials.
Keyphrases
- endometrial cancer
- clinical trial
- decision making
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- randomized controlled trial
- single cell
- patient reported outcomes
- stem cells
- dna repair
- oxidative stress
- mesenchymal stem cells
- combination therapy
- study protocol
- cell therapy
- patient reported
- smoking cessation
- double blind
- placebo controlled